Lonza to Build Cell Therapy Production Facility in Singapore

Lonza says it will build a new cell therapy manufacturing facility in Singapore to expand its global presence and to meet the growing worldwide demand for cell therapies. The facility will be located adjacent to Lonza’s large-scale mammalian manufacturing facility at Tuas Biomedical Park in Singapore. The first phase of the facility will involve an investment of SF30 million ($27 million). Construction of the facility will begin in early 2010 and it is expected to start manufacturing therapies in the first two suites by mid 2011. The facility will be...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers